Actions
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
2
Neutral
5
Bullish
7
Bearish
28
Neutral
5
Bullish
13
Bearish
26
Neutral
0
Bullish
6
Bearish
26
Neutral
0
Bullish
6
Bearish
26
Neutral
0
Bullish
6
Bearish
26
Neutral
0
Bullish
6
Investor Presentation
Q2 FY27
Investor Presentation
Q4 FY26
Aakaar Medical Technologies Ltd (AAKAAR) is currently trading at 66.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Aakaar Medical Technologies Limited distributes medical-aesthetic products and devices to dermatologists, plastic surgeons and aesthetic physicians, combining imported brands with domestically marketed own brands and a developing doctor-led clinic ecosystem. H1 FY27 revenue from operations reached INR43.72 crore, up 72.64% year-on-year, while PAT recovered to INR3.54 crore from an INR0.80 crore loss. The turnaround reflects stronger execution, broader doctor coverage and improved demand after a weak prior-year first half. The company is investing aggressively in future demand: H1 marketing expenditure was approximately INR3.4 crore, exceeding the full-year FY26 spend. This investment supported conferences, workshops, digital activity and doctor acquisition, but temporarily compressed gross and operating margins. Working capital remains the key execution issue. Debtor days increased to 219 from 206, cash fell to INR1.05 crore from INR16.2 crore, and management is relying on a distributor-led model to improve collections, reduce doctor-level exposure and potentially bring receivables substantially lower. Aakaar is expanding beyond product distribution through Xelix Clinics, FotoFinder devices, Letybo botulinum toxin and a proprietary hair-transplant device under regulatory development. These initiatives could improve differentiation and recurring revenue, but their commercial outcomes remain dependent on approvals, adoption and disciplined capital management.
Over the past 52 weeks, Aakaar Medical Technologies Ltd has traded between a low of ₹46.00 and a high of ₹84.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Aakaar Medical Technologies Ltd has a market capitalization of approximately 93.54. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Aakaar Medical Technologies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 8.53 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 93.54 Cr, Aakaar Medical Technologies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Aakaar Medical Technologies Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Aakaar Medical Technologies Ltd is 8.53. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Aakaar said receivable days increased to about 220 from 160 last year while it completed its Novacare migration and started a distributor model. Management said its end customers are doctors, making collection timing a material part of the working-capital cycle.
Aakaar reported profit after tax of Rs 3.54 crore in H1 FY27, equal to an 8.05% PAT margin. In H1 FY26, Aakaar recorded a Rs 80 lakh loss, making the latest half a return to profitability.
Aakaar Xelix is a platform for doctor-owned and doctor-operated aesthetic clinics. Aakaar intends to help consumers identify qualified dermatologists and plastic surgeons, with a call centre directing enquiries to suitable doctors.
Aakaar Medical Technologies Ltd. reported revenue from operations of INR 43.72 crore in H1 FY27. This was 72.6% higher than INR 25.32 crore reported in H1 FY26.
Healthcare Equipment & Supplies
Medical Equipment & Supplies
94 Cr
Low Risk
8.5
60.1
0.3
1.7
84.95
46.00
Sales CAGR
Profit CAGR
ROE
ROCE